High materiality8/10
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Piper Sandler downgraded SUPN to Neutral, citing unmet Qelbree prescription growth. Qelbree sales grew 92% YoY but long-term growth assumptions are re-evaluated. Peak sales projections for Qelbree adjusted from $500M to $400M. FDA granted resubmission of SPN-830’s NDA, with PDUFA date set for Feb 2025. SUPN stock fell 7.17%, reflecting market reactions to the downgrade.
- Piper Sandler downgraded SUPN to Neutral, citing unmet Qelbree prescription growth.
- Qelbree sales grew 92% YoY but long-term growth assumptions are re-evaluated.
- Peak sales projections for Qelbree adjusted from $500M to $400M.
- FDA granted resubmission of SPN-830’s NDA, with PDUFA date set for Feb 2025.
- SUPN stock fell 7.17%, reflecting market reactions to the downgrade.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.